Endologix Inc. (ELGX) Misses Street View By 2c; Cuts Guidance
More News related to ELGX
- Endologix (ELGX) Reports Powerlink XL Trial Met Primary Endpoint
- Endologix Announces Favorable Powerlink XL Clinical Trial Results
- Endologix Responds to Unsolicited Proposal from Elliott Associates
- Favorable Endologix Powerlink XL System Clinical Data to Be Announced November 20 at Veith Symposium
- Endologix to Present at the Stephens Fall Investment Conference
More News related to Earnings
- Form 4 TROTMAN STANLEY S JR For: Nov 26
- Form 4 ALLIED MOTION TECHNOLOGI For: Dec 01 Filed by: SMITH RICHARD D /CO/
- Form 4 Stais Anthony V For: Dec 01
- Form 4 Kordestani Omid For: Dec 01
- Form 4 EPICOR SOFTWARE CORP For: Nov 26 Filed by: ELLIOTT INTERNATIONAL, L.P.
Endologix Inc. (Nasdaq: ELGX) reports Q2 loss of $0.09 versus the analyst estimate of ($0.05). Revenues for the quarter were $9.3 million, versus the consensus of $9.5 million.
Cuts revenue guidance for the year.
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
